Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. More Details
High growth potential with imperfect balance sheet.
Share Price & News
How has Rigel Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RIGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: RIGL's weekly volatility has decreased from 16% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: RIGL exceeded the US Biotechs industry which returned 20.7% over the past year.
Return vs Market: RIGL exceeded the US Market which returned 42.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Rigel Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWhen Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Breakeven?
1 month ago | Simply Wall StIt's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year
2 months ago | Simply Wall StWhat Is The Ownership Structure Like For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)?
Is Rigel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RIGL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RIGL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RIGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RIGL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RIGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RIGL is overvalued based on its PB Ratio (9.2x) compared to the US Biotechs industry average (3.4x).
How is Rigel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RIGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: RIGL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RIGL's is expected to become profitable in the next 3 years.
Revenue vs Market: RIGL's revenue (23.8% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: RIGL's revenue (23.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RIGL's Return on Equity is forecast to be high in 3 years time
How has Rigel Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RIGL is currently unprofitable.
Growing Profit Margin: RIGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RIGL is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare RIGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RIGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: RIGL has a negative Return on Equity (-14.67%), as it is currently unprofitable.
How is Rigel Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RIGL's short term assets ($196.8M) exceed its short term liabilities ($52.0M).
Long Term Liabilities: RIGL's short term assets ($196.8M) exceed its long term liabilities ($85.7M).
Debt to Equity History and Analysis
Debt Level: RIGL's debt to equity ratio (98.8%) is considered high.
Reducing Debt: Insufficient data to determine if RIGL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RIGL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RIGL has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.1% each year.
What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RIGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RIGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RIGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RIGL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RIGL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raul Rodriguez (59 yo)
Mr. Raul R. Rodriguez has been the Chief Executive Officer of Rigel Pharmaceuticals, Inc., since November 2014 and has been its President since May 2010. Mr. Rodriguez served as Chief Operating Officer at ...
CEO Compensation Analysis
Compensation vs Market: Raul's total compensation ($USD2.96M) is about average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Raul's compensation has increased whilst the company is unprofitable.
Experienced Management: RIGL's management team is considered experienced (3.1 years average tenure).
Experienced Board: RIGL's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rigel Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Rigel Pharmaceuticals, Inc.
- Ticker: RIGL
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$719.795m
- Shares outstanding: 170.16m
- Website: https://www.rigel.com
Number of Employees
- Rigel Pharmaceuticals, Inc.
- 1180 Veterans Boulevard
- South San Francisco
- United States
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 02:36|
|End of Day Share Price||2021/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.